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Abstract
Introduction:  Ovarian stimulation is employed in assisted reproduction
techniques in order to obtain as many oocytes as possible. The early rise in
oestradiol levels may lead to the premature end of the respective cycle. In order
to avoid such an effect, pituitary suppression has been employed. The aim of
this study was to evaluate whether maintenance or replacement of the type of
GnRH analogue (i.e., agonist or antagonist) employed for pituitary suppression
in the consecutive intracytoplasmic sperm injection (ICSI) cycle would negatively
influence oocyte quality and ICSI outcome.
Material and methods: A retrospective observational study was conducted
including 181 women with primary infertility. Patients were divided into four
different groups according to the GnRH analogue used for pituitary suppression
in the first and consecutive cycle.
Results: When a GnRH agonist was employed for pituitary suppression in the
first cycle, the consecutive cycle showed comparable outcomes when performed
with either a GnRH agonist or a GnRH antagonist. When the first cycle was
performed with a GnRH antagonist, the use of the GnRH agonist in the
successive cycle led to an increased number of oocytes retrieved (7.5% vs. 10.3%,
p = 0.032) and the production of a higher number of embryos (4.5% vs. 6.3%,
p = 0.036).
Conclusions: When the first cycle is carried out with a GnRH antagonist, the use
of a GnRH agonist in the successive cycle would lead to increased numbers of
oocytes collected and embryos produced.
Key words: controlled ovarian stimulation, GnRH agonist, GnRH antagonist,
intracytoplasmic sperm injection.
Introduction
Ovarian stimulation, a standard procedure used in assisted reproductive
technologies [1], is employed aiming to stimulate the growth of several
follicles and, consequently, obtain as many high quality oocytes as possible.
In controlled ovarian stimulation (COS) protocols, the early rise in oestradiol
levels may promote an extemporaneous LH surge, leading to the premature
end of the respective cycle. In order to avoid such an effect, over the last
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20 years, pituitary suppression has been employed.
Initially, pituitary suppression was attempted using
GnRH agonists and, more recently, GnRH
antagonists were introduced [2, 3].
Previous studies indicated that GnRH antagonists
were related to lower pregnancy and implantation
rates [4-7]. However, recent studies do not support
such conclusions [8-11], especially when avoiding
initiation of ovarian stimulation in patients showing
high progesterone levels [12, 13] and when providing
LH activity supplementation during the late follicular
phase [1]. 
Another issue that remains controversial is
whether ovarian response is affected by
consecutive COS. While some investigations have
suggested that repeated COS cycles lead to
a decrease in the number of collected oocytes [14],
other studies do not agree with such an effect [15,
16]. The aim of the present investigation is to
evaluate whether maintenance or replacement of
the type of GnRH analogue (i.e., agonist or
antagonist) employed for pituitary suppression in
the consecutive intracytoplasmic sperm injection




We retrospectively evaluated 181 women with
primary infertility undergoing two consecutive ICSI
cycles within a 3-month interval. The patients
included in the study had an unsuccessful result in
the first attempt and no cryopreserved embryos for
a thawed embryo transfer; therefore a second ICSI
cycle was performed. 
All patients included in the study underwent the
second ICSI cycle after the first attempt had failed.
Patients showing the following characteristics 
were excluded from the study: (i) Body mass index
≥ 30 kg/m2, (ii) blood serum FSH > 10 mU/ml on
day 3 of the menstrual cycle, (iii) presence of
clinically significant systemic disease, (iv) presence
of endometriosis grades III-IV, (v) previous ovarian
surgery, and (vii) presence of polycystic ovarian
syndrome. 
The distribution of the infertility causes among
the groups is described in Table I. Informed written
consent in which patients agreed to share the
outcomes of their own cycles for research purposes
was obtained. The study was approved by the local
institutional review board.
Patients were divided into four different groups
according to the GnRH analogue used for pituitary
suppression: (i) group I: GnRH agonist in the first
and second cycles of COS (n = 66); (ii) group II:
GnRH agonist in the first cycle and GnRH antagonist
in the second (n = 52); (iii) group III: GnRH
antagonist in both the first and second cycles of
COS (n = 36); (iv) group IV: GnRH antagonist and
GnRH agonist in the first and second cycle,
respectively (n = 27). 
The endpoints of this study were total dose of
r-FSH administered, number of metaphase II (MII)
oocytes retrieved, number of embryos produced,
and ongoing pregnancy rates in the second
attempt. An ongoing pregnancy is defined as an
intrauterine pregnancy with the presence of fetal
heart beats 11-12 weeks after embryo transfer.
Controlled ovarian stimulation
In cycles in which a GnRH agonist was employed,
ovarian stimulation was performed as follows: 1 mg
leuprolide acetate (Lupron Kit®, Abbott S.A. Societé
Française des laboratories, Paris, France) was
administered subcutaneously from day 18 of the
previous menstrual cycle. After 12 to 14 days, the
dose of GnRH agonist was reduced to 0.5 mg and
ovarian stimulation was achieved with a fixed daily
dose of 225 IU of r-FSH (Gonal F®, Serono, Geneve,
Switzerland). 
In cycles in which a GnRH antagonist was used,
ovarian stimulation started on days 2-3 of the
menstrual cycle with a fixed dose of 225 IU of r-FSH
on a daily basis. When at least one follicle ≥ 14 mm
was visualized 0.25 mg of cetrorelix acetate
(Cetrotide®, Serono, Geneve, Switzerland) was
administered subcutaneously, until the day of hCG
triggering injection.
For both pituitary blockage regimens, when
adequate follicular growth and serum oestradiol
levels were observed, recombinant human chorionic
gonadotrophin was administered to trigger the final
follicular maturation. Oocytes were collected 35 h
after hCG administration by transvaginal ultrasound
ovum pick-up.
Infertility cause I (n = 66) II (n = 52) III (n = 36) IV (n = 27) Value of p
Male factor 60.6% 57.7% 55.5 % 66.6% 0.657
Idiopathic 9.09% 11.5% 13.8% 11.1% 0.612
Poor response 27.2% 25.0% 27.7%  18.5% 0.328
Other 3.03% 5.7% 2.7% 3.7 % 0.525
Table I. Distribution of infertility cause among the groups472 Arch Med Sci 3, June / 2011
Sperm samples
Ejaculated spermatozoa were obtained by
masturbation after 3-5 days of ejaculatory
abstinence. After liquefaction at room temperature,
sperm samples were selected by swim up, which
was performed by diluting semen samples in
a Hepes-buffered medium (1 : 1; Irvine Scientific,
Santa Ana, USA) and incubating at 37°C for 1 h,
allowing spermatozoa to move from the seminal
plasma to the overlayered culture medium. 
Preparation of oocytes 
After retrieval, oocytes were placed in culture
medium (G-1™-V1, Vitrolife, Kungsbacka, Sweden),
Vitrolife, Kungsbacka, Sweden) covered with mineral
oil (Ovoil™, Vitrolife, Kungsbacka, Sweden) and
incubated at 37°C in 6% CO2 for 5 h. Cumulus cells
were removed with a 30 s exposure to a Hepes-
buffered medium containing 80 IU/ml hyal  -
uronidase (Irvine Scientific, Santa Ana, USA).
Coronal cells were then manually removed using
a finely drawn glass Pasteur pipette (Humagen
Fertility Diagnostics, Charlottesville, Virginia, USA). 
Denuded oocytes were then assessed for nuclear
status. Oocytes showing the release of the first polar
body were considered mature and used for ICSI. 
Intracytoplasmic sperm injection
For ICSI, oocytes were placed individually in 4 μl
droplets of buffered medium (G-Mops™-V1, Vitrolife,
Kungsbacka, Sweden). Sperm was placed in
a central 4 μl droplet of polyvinylpyrrolidone solution
(PVP, Irvine Scientific, Santa Ana, USA) in a 60 ×
15 Mm plastic culture dish (Corning, Massachusetts,
USA) covered with warm mineral oil (Ovoil™,
Vitrolife, Kungsbacka, Sweden). Sperm injection was
carried out on the heated stage (37°C) of an
inverted microscope (Eclipse TE 300; Nikon®, Tokyo,
Japan) 40 h after hCG trigger
Statistical analysis
Categorical variables were analysed using χ2 or
Fisher test as appropriate. Student’s t-test was
employed when the numerical variables showed
a normal distribution. Results were then described
as mean and standard deviation. Non-parametric
analysis (Mann-Whitney test) was performed for
non-normally distributed data. In this case, median
and range were used for results description. 
Results were considered to be significant at the
5% critical level (p < 0.05). Data analysis was carried
out using Minitab (version 14).
Results
In both groups submitted to the GnRH agonist
in the first cycle, patients’ mean ages were 34.29
±4.69 and 35.85 ±3.81 years for groups I and II,
respectively (p = 0.658). Also for these groups, the
interval between cycles was 68.23 ±15.68 and 56.40
±19.25 days for groups I and II, respectively 
(p = 0.494). The outcomes of ovarian stimulation
in these groups are presented in Table II.
For patients in group I, no differences were found
between the first and second cycle for any variable.
When patients were treated with the GnRH agonist
in the first cycle and subsequently with the
antagonist in the second cycle (group II),
a significant increase in the number of retrieved MII
oocytes was observed. This, however, was not
followed by an increase in the number of embryos
produced. No differences were found in pregnancy
rates between groups I and II (21.2% vs. 28.8%,
respectively; p = 0.398; Table III).
The mean ages of patients submitted to the
GnRH antagonist in the first cycle were 36.9 ±5.0
and 35.9 ±5.0 years for groups III and IV, respectively
(p = 0.459). Moreover, the mean intervals between
cycles were 54.7 ±16.4 and 69.7 ±23.5 days for
groups III and IV, respectively (p = 0.254). 
The outcomes of ovarian stimulation in these
groups are presented in Table II. A significant
increase in r-FSH dose administered was observed
in group III when comparing the first and the
second cycles. When, instead of the GnRH
antagonist of the first cycle, an agonist was used
in the second cycle (group IV), significant increases
in the number of retrieved MII oocytes and in the
number of embryos produced were observed.
However, no differences were found between
groups III and IV in pregnancy rates (19.5% vs.
22.2%, respectively; p = 0.877; Table III).
Regarding the number of transferred embryos,
no significant difference was found when
comparing the first and second attempt for groups
I, II, III and IV (Table II).
Discussion
The response to ovarian stimulation depends on
several parameters such as woman’s age and
ovarian reserve status. Whether or not repeated
and consecutive COS cycles impair the outcomes
of the procedure is controversial. Kolibianakis et al.
[14] conducted a retrospective analysis with 3,249
patients submitted to at least two COS cycles, and
registered an age-independent deterioration of
ovarian response across repeated cycles. On the
other hand, de Boer et al. [15], studying 330 women
undergoing consecutive ICSI cycles, observed no
decrease in the number of retrieved oocytes over
subsequent cycles. Moreover, Caligara et al. [17]
reported that, in young oocyte donor women,
successive COS cycles do not impair ovarian
response in terms of the number of oocytes
obtained.
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The present study aimed to investigate whether
consecutive COS impairs the outcome of ICSI cycles,
requiring higher amounts of r-FSH or promoting
a lower ovarian response, in terms of MII oocytes
retrieved and number of embryos produced. Our
investigation studied not only the effects of
repeating the cycle within 3 months, but also
whether by modifying the nature of GnRH analogue
used to achieve pituitary suppression, different
outcomes could be achieved. 
According to our results, patients submitted to
the GnRH agonist in the first cycle suffered no
deleterious effects regarding ovarian stimulation
outcomes when a second ICSI cycle was performed
within 3 months. In addition, we observed that
when a GnRH agonist is used in the first attempt,
the use of either a GnRH agonist or an antagonist
in the second cycle leads to similar outcomes.
However, when patients were submitted to the
GnRH agonist in the first cycle followed by an
antagonist in the second (group II), the number of
MII oocytes retrieved was higher when compared
to the GnRH agonist in both cycles (group I). 
In groups in which pituitary suppression in the
first cycle was performed with the GnRH antagonist,
an increase in r-FSH requirements was observed
when the antagonist was maintained in the second
attempt, despite previous experiments indicating
that the use of GnRH antagonist in ovarian
stimulation protocols is associated with lower
requirements of FSH (Tarlatzis and Kolibianakis,
2007; Kurzawa et al., 2008). Even with increased
amounts of r-FSH in the second cycle with the
GnRH antagonist, no differences were found in the
number of oocytes retrieved and embryo
production. On the other hand, when the GnRH
antagonist used in the first cycle is replaced by an
agonist in the consecutive cycle, a higher number
of MII oocytes collected and a higher number of
embryos produced were observed. 
In fact, in two situations, an increased number
of retrieved MII oocytes could be observed. The first
was when the pituitary blockage was performed
initially through a GnRH agonist and subsequently
using a GnRH antagonist. In this case, however, the
number of embryos was not higher. In the second
situation the use of a GnRH antagonist followed by
a GnRH agonist led to a higher number of MII and
also a higher number of embryos. 
GnRH agonists have the same effect on
gonadotropin release after binding the receptor as
native GnRH. The main difference of GnRH agonists
n Groups First cycle Second cycle Value of p
Agonist Antagonist Agonist Antagonist
Total r-FSH  66 I 2,447.7 ±628.9 – 2,583.7 ±765.6 – 0.121
dose 52 II 2,628.8 ±542.9 – – 2,790.4 ±626.9 0.078
administered (IU)
36 III – 2,509.8 ±593.2 – 2,888.2 ±761.8 0.001
27 IV – 2,652.0 ±666.9 2,831.0 ±796.0 – 0.179
Number of MII  66 I 8.9 ±6.8 – 9.5 ±6.7 – 0.288
oocytes collected 52 II 5.0 ±3.7 – – 6.5 ±4.7 0.024
36 III – 7.2 ±5.5 – 7.3 ±6.4 0.909
27 IV – 7.5 ±6.9 10.3 ±8.4 – 0.032
Number of  66 I 4.8 ±3.2 – 5.8 ±4.2 – 0.088
embryos 52 II 3.0 ±2.3 – – 3.8 ±2.3 0.090
produced
36 III – 4.4 ±3.0 – 4.8 ±3.7 0.440
27 IV – 4.5 ±3.5 6.3 ±5.2 – 0.036
Number of  66 I 3.07 ±0.15 3.05 ±0.15 0.248
transferred 52 II 2.46 ±0.33 2.76 ±0.41 0.367
embryos
36 III 2.93 ±0.26 3.01 ±0.23 0.389
27 IV 2.80 ±0.28 2.80 ±0.26 0.452
Table II. Outcomes of ovarian stimulation in patients submitted to two consecutive ICSI cycles, based on the nature
of the GnRH analogue (agonist and antagonist) used for pituitary suppression in each cycle
Groups First cycle Second cycle Pregnancy rate
I Agonist Agonist 14/66 (21.21%)
II Agonist Antagonist 15/52 (28.84%)
III Antagonist Antagonist 7/36 (19.5%)
IV Antagonist Agonist 6/27 (22.2%)
Table III. Pregnancy rates in patients submitted to
two consecutive ICSI cycles, based on the nature of
the GnRH analogue (agonist and antagonist) used
for pituitary suppression in each cycle474 Arch Med Sci 3, June / 2011
used in clinical practice, in comparison with native
GnRH, is that the half-life time and the
bioavailability are prolonged, due to increased
lipophilicity [18]. The continuous administration of
GnRH agonists (daily or depot application) initially
causes LH and FSH hypersecretion (flare-up), which
is followed after a period of about 10 days by
desensitization of the pituitary and profound
suppression of LH and FSH [19]. The lack of
pulsatile secretion of LH and FSH during long-term
treatment with GnRH agonists results in the arrest
of follicular growth at the gonadotrophin-
dependent stage [20, 21].
Unlike GnRH agonists, the antagonists do not
induce an initial hypersecretion of gonadotropins
but instead cause an immediate and rapid reversible
suppression of gonadotropin secretion. The principal
mechanism of action of GnRH antagonists is
competitive occupancy of the GnRH receptor. Their
administration results in the suppression of LH
(about 70%) and FSH (about 30%) serum levels
after about 6 h [22-24].
Our results demonstrated that different protocols
for pituitary blockage, in two consecutive cycles,
have positive effects on the response to the COS.
Why repetitive pituitary blockage protocols may
have detrimental effects on the gonadotrophs is
still a matter of debate. However, we suggest that
the different mechanism of action of the two GnRH
analogues may be responsible for the improved
response to the COS. 
Regarding the requirements of r-FSH, we also
observed an increase in the total dose
administered, although statistical significance was
not achieved. This could be due to a higher
inhibitory effect of the GnRH antagonist in ovaries
on the consecutive cycle, since it is well established
that specific GnRH receptors are present in human
granulosa cells [25].
Both forms of GnRH receptors, GnRH I and 
GnRH II, are expressed in various compartments of
the human ovary, so that GnRH and its analogues
not only influence steroidogenesis, but also induce
a decrease in proliferation and promote apoptosis
of the ovarian cells [26]. When pituitary suppression
is performed with a GnRH antagonist, the inhibitory
effects of the analogue on the granulosa cells are
more pronounced, and a second consecutive cycle
would require higher amounts of r-FSH to stimulate
follicular development. This hypothesis is
corroborated by the findings of Giampietro et al.
[27], who compared the levels of apoptosis in
granulosa cells from women treated with a GnRH
agonist or a GnRH antagonist and found that the
mean concentrations of oestradiol, testosterone
and progesterone in the follicular fluid were
significantly lower in the GnRH antagonist treated
group.
Even if we cannot exclude a possible bias
associated with the retrospective analysis of the
data, our findings suggest that, when a COS cycle
with GnRH antagonist has an unsuccessful
pregnancy outcome, a consecutive cycle performed
within 3 months should be repeated switching to
the GnRH agonist protocol, in order to achieve
better outcomes, at least with regard to the number
of oocytes collected and embryos produced.
In conclusion, the data of the present
investigation suggest that there are no deleterious
effects of consecutive ovarian stimulation cycles,
in terms of retrieved oocytes and embryo
production. When a GnRH agonist is employed for
pituitary suppression in the first cycle, the
consecutive cycle shows comparable outcomes
when performed with either a GnRH agonist or
a GnRH antagonist. On the other hand, when the
first cycle is carried out with a GnRH antagonist,
our data suggest that the use of a GnRH agonist in
the successive cycle may promote the retrieval of
a higher number of oocytes and the consequent
production of a higher number of embryos.
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